Evidence map›Paper›PMID 42323781›Full record

ArticleInfectious diseases and therapy2026

Forecasting the Multidimensional Burdens of Hospital Admissions in LRTIs and COPD: Projections of Healthcare Expenditures, Resource Utilization, and Socioeconomic and Environmental Outcomes for Switzerland.

Desiree Schnidrig, Thomas Campbell-James, Josia D Schramm, Noel Ackermann, Lindsay Nicholson, Michel Fries, Samuel C Robson, Jörg D Leuppi, Patrick E Beeler

Abstract read
In one paragraph

Article in Infectious diseases and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Desiree Schnidrig *Institute of Life Sciences and Healthcare, School of Medicine, Pharmacy and Biomedical Sciences, Faculty of Science and Health, University of Portsmouth, Portsmouth, UK.ORCID http://orcid.org/0000-0002-7947-7666
Thomas Campbell-James *Medical Affairs, AstraZeneca AG, Zug, Switzerland. thomas.campbell-james@astrazeneca.com.ORCID http://orcid.org/0000-0003-1648-0515
Josia D SchrammFaculty of Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland.ORCID http://orcid.org/0009-0001-0638-6501
Noel AckermannFaculty of Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland.ORCID http://orcid.org/0009-0000-9340-4917
Lindsay NicholsonMaverex Limited, Newcastle Upon Tyne, UK.ORCID http://orcid.org/0009-0001-3088-7197
Michel FriesMedical Affairs, AstraZeneca AG, Zug, Switzerland.ORCID http://orcid.org/0009-0008-7764-1056
Samuel C RobsonInstitute of Life Sciences and Healthcare, School of Medicine, Pharmacy and Biomedical Sciences, Faculty of Science and Health, University of Portsmouth, Portsmouth, UK.ORCID http://orcid.org/0000-0001-5702-9160
Jörg D LeuppiUniversity Institute of Internal Medicine, Cantonal Hospital Baselland, Liestal, Switzerland.ORCID http://orcid.org/0000-0002-5554-0675
Patrick E BeelerFaculty of Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland.ORCID http://orcid.org/0000-0002-6097-2480

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionHospital admissions due to lower respiratory tract infections (LRTIs) and chronic obstructive pulmonary disease (COPD) represent a substantial healthcare challenge for Switzerland. Demographic shift is expected to exacerbate the burden. Thus, multidimensional projections of healthcare resource utilization, environmental, and (socio)economic impact are necessary to facilitate sustainable healthcare planning for these diseases.

methodsBRONCH-2035 employed historical admissions data (2015-2023) and Swiss governmental population scenario forecasts to project nationwide hospital and intensive care unit (ICU) admissions due to LRTIs and COPD between 2025 and 2035. Projections were then leveraged to estimate future inpatient healthcare expenditures, environmental and socioeconomic burden, employing historic tariff data (SwissDRG) alongside data on disease-agnostic greenhouse gas emissions, Swiss governmental employment and Organization for Economic Co-operation and Development (OECD) economic activity.

resultsCompared to 2025, 10,055 (18.4%) additional hospitalizations and an additional 488 (14.3%) ICU admissions due to LRTI and COPD were projected for 2035, requiring 338 (21.8%) additional hospital and 7 (15.9%) surplus ICU beds. Future admissions are estimated to result in an additional 100.2 million Swiss francs (CHF) (18.3%) in inpatient healthcare expenditures and 1.3 million kg (21.1%) additional CO

conclusionsBRONCH-2035 is the first study to project the healthcare, environmental and socioeconomic burdens in LRTI and COPD for Switzerland. Population growth and demographic shift alone are projected to exacerbate LRTI and COPD hospitalizations, ICU admissions, inpatient healthcare expenditures, and bed requirements by 2035, alongside socioeconomic and environmental consequences. These findings provide a robust baseline for healthcare planning, highlighting the need for consistent guideline-concordant prevention and structured outpatient care.

Indexed as

AdmissionsBRONCH-2035Burden of diseaseChronic obstructive pulmonary diseaseCOPDCostsEnvironmental impactEpidemiologyHCRUHealthcare expendituresHealthcare resource utilizationHospitalizationsLower respiratory tract infectionLRTISocioeconomic outcomesSwitzerland

Identifiers

PMID42323781
PMCPMC13350596

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.